))
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer
Manage episode 446254541 series 3560609
Jacqueline Stone and Oncololgy News Central에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Jacqueline Stone and Oncololgy News Central 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD, director of the clinical trials office, chief clinical research officer, and associate director for clinical sciences at Yale Cancer Center in New Haven, Connecticut. He and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss how oncologists should best approach HER2 testing, ADC sequencing, and toxicity concerns. When it comes to answering key questions, “We're a little data-poor in some ways because this is such a rapidly evolving field,” Dr. Krop explains. He also considers what’s next for ADCs in breast cancer, including the potential for those treatments to move into the curative early-disease setting.
Dr. Krop reported various financial relationships.
Dr. Figlin reported various financial relationships.
130 에피소드
공유
